Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18815386 | AUTOBIOTIC COMPOSITIONS AND METHOD FOR PROMOTING HEALTHY GUT MICROBIOME | August 2024 | June 2025 | Allow | 9 | 2 | 0 | No | No |
| 18196574 | METHOD FOR TREATING PARKINSON’S DISEASE BY USING PARABACTEROIDES GOLDSTEINII | May 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17820638 | Device and a Method for Immobilization of Proteins, Enzymes or Cells | August 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17792176 | MYCELIUM MATERIALS, AND METHODS FOR PRODUCTION THEREOF | July 2022 | October 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17680201 | SPECTRAL INTENSITY RATIO (SIR) ANALYSIS FOR RAPID LIVE MICROBIAL ENUMERATION | February 2022 | March 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17671463 | METHODS AND KITS FOR PRODUCING A FIBRIN MATRIX | February 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17633064 | COMPOSITIONS OF PROBIOTICS AND BIOMASS AND METHODS FOR PROMOTING HEALTH IN A SUBJECT | February 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17560432 | HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF | December 2021 | October 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17596346 | CARBON COMPOUND PRODUCTION IN PHOTOSYNTHETIC MICROORGANISMS | December 2021 | November 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17530517 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17609931 | METHOD OF EXTRACTING PROTEIN FROM SEA LETTUCE | November 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17440064 | METHOD FOR PRODUCING CARBON-BASED PRODUCTS FROM SECONDARY RAW MATERIALS CONTAINING PH REGULATORS | October 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17473910 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD | September 2021 | October 2025 | Allow | 49 | 2 | 0 | No | No |
| 17432929 | MATE AND SEPARATE: A CONVENIENT AND GENERAL METHOD FOR THE SEPARATION AND PURIFICATION OF TARGET MOLECULES FROM BIOLOGICAL MEDIA BY PHASE TRANSITION OF PEGYLATED RECOGNITION AGENTS. | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17406339 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | August 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17428375 | TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION WITH SPECIFIC CARBOHYDRATE DIET | August 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17421721 | Food Supplement For Improving Sports Performance | July 2021 | December 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17294065 | METHOD FOR IDENTIFYING 2'O-METHYLATION MODIFICATION IN RNA MOLECULE, AND APPLICATION THEREOF | May 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17235450 | CELL-FREE METABOLIC PATHWAY OPTIMIZATION THROUGH REMOVAL OF SELECT PROTEINS | April 2021 | October 2025 | Abandon | 53 | 3 | 1 | No | No |
| 17284744 | CRISPR SYSTEM FOR GENOME EDITING | April 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17224596 | RECOMBINANT MICROORGANISM INCLUDING GENETIC MODIFICATION THAT INCREASES ACTIVITY OF NITRIC OXIDE REDUCTASE AND METHOD OF REDUCING CONCENTRATION OF NITRIC OXIDE IN SAMPLE BY USING THE SAME | April 2021 | October 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 17268721 | SYNTHESIS OF DNA WITH IMPROVED YIELD | February 2021 | November 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17160181 | MANUFACTURING METHOD OF HIGH-EFFICIENCY PLANT COMPOSITE TYPE BACTERIOSTATIC DEODORANT BASED ON HQ22 BEAN EXTRACT | January 2021 | October 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17114220 | MANUFACTURING OR ONSIDE INSTALLATION OF COMPOSITIONS WITH METHODS, SYSTEMS TO ADDRESS ECOLOGICAL AND ECONOMICAL CONCERNS OF THE AQUACULTURE INDUSTRY | December 2020 | October 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17026359 | GENOME-WIDE RATIONALLY-DESIGNED MUTATIONS LEADING TO ENHANCED TYROSINE PRODUCTION IN S. CEREVISIAE | September 2020 | February 2023 | Abandon | 29 | 0 | 1 | No | No |
| 16980582 | A HEPATOCYTE-MIMICKING ANTIDOTE FOR ALCOHOL INTOXICATION | September 2020 | February 2023 | Abandon | 29 | 1 | 1 | No | No |
| 16926423 | NOVEL APPLICATIONS OF PULSED ELECTRIC FIELD AND E-BEAM TECHNOLOGY | July 2020 | January 2023 | Abandon | 30 | 1 | 0 | No | No |
| 16769402 | METHODS AND PRODUCTS FOR BIODEGRADATION OF WASTE | June 2020 | November 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16754247 | PRODUCTION OF STEVIOL GLYCOSIDES IN RECOMBINANT HOSTS | April 2020 | February 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16653452 | White Blood Cell Analysis System and Method | October 2019 | April 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16467529 | APPARATUS, SYSTEMS, AND METHODS FOR VASCULAR TISSUE PERFUSION | June 2019 | February 2023 | Abandon | 45 | 0 | 1 | No | No |
| 16389577 | Cannabinoid Production by Synthetic In Vivo Means | April 2019 | February 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16368808 | LYTIC PEPTIDE BIOSENSOR AND METHODS OF MAKING AND USING THE SAME | March 2019 | November 2019 | Abandon | 7 | 0 | 0 | No | No |
| 16326609 | LIVER PRESERVATION METHOD AND OPERATION METHOD | February 2019 | January 2023 | Abandon | 46 | 0 | 1 | No | No |
| 16321880 | Method for Producing Soyasaponins | January 2019 | January 2021 | Abandon | 23 | 0 | 1 | No | No |
| 16197435 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM | November 2018 | November 2020 | Abandon | 24 | 0 | 1 | No | No |
| 16099889 | Universal Calibration Method for Assaying Enzymatic Inhibitors | November 2018 | August 2022 | Abandon | 46 | 3 | 1 | No | No |
| 16090867 | BIFIDOBACTERIA FOR INCREASING LEAN BODY MASS | October 2018 | November 2020 | Abandon | 25 | 1 | 0 | No | No |
| 16141687 | PREBIOTIC BACTERIOPHAGE CONTAINING COMPOSITION FOR TREATMENT OF GASTROINTESTINAL INFLAMMATION | September 2018 | August 2025 | Allow | 60 | 7 | 1 | No | No |
| 16106138 | CENTRIFUGATION AND FILTRATION METHODS FOR CONCENTRATING MICROORGANISMS | August 2018 | January 2021 | Abandon | 28 | 1 | 0 | Yes | No |
| 16104549 | Probiotic Solution | August 2018 | November 2020 | Abandon | 27 | 1 | 0 | No | No |
| 16101449 | COMPOSITES HAVING NOVEL ANTI-FOULING COMPONENTS AND METHODS OF MANUFATURE | August 2018 | January 2021 | Abandon | 29 | 0 | 1 | No | No |
| 16070779 | CULTURE MEDIUM FOR DETECTING ENTEROCOCCUS AND METHOD FOR DETECTING SAME | July 2018 | February 2021 | Abandon | 31 | 1 | 0 | No | No |
| 16022429 | METAL-CHELATE COMPLEX HYDROGEN SULFIDE SCAVENGERS | June 2018 | November 2020 | Abandon | 29 | 1 | 0 | No | No |
| 16015668 | Method of Increasing Probiotic Viability in Food Products | June 2018 | July 2021 | Abandon | 37 | 2 | 0 | No | No |
| 15984576 | CONVERSION SYSTEM FOR BIOMASS | May 2018 | March 2019 | Abandon | 10 | 1 | 0 | No | No |
| 15655537 | ADHERENT STROMAL CELLS DERIVED FROM PLACENTAS OF MULTIPLE DONORS AND USES THEREOF | July 2017 | January 2023 | Abandon | 60 | 4 | 0 | No | No |
| 15612459 | Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them | June 2017 | June 2019 | Abandon | 24 | 1 | 0 | Yes | No |
| 15501041 | DETECTION OF PROTEIN ARGININE DEMETHYLASE ACTIVITY | February 2017 | April 2020 | Abandon | 39 | 1 | 1 | No | No |
| 15420060 | IN VITRO CELLULAR ANALYSIS | January 2017 | November 2022 | Abandon | 60 | 4 | 1 | No | No |
| 15325891 | METHOD FOR PRODUCING GAMMA-GLUTAMYLCYSTEINE AND GLUTATHIONE | January 2017 | August 2020 | Abandon | 43 | 2 | 1 | No | No |
| 15317867 | SYSTEM AND METHODS FOR APPLYING CONTROLLED LOW-INTENSITY ULTRASOUND TO A CELL CULTURE | December 2016 | March 2019 | Abandon | 27 | 0 | 1 | No | No |
| 15369105 | METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASE | December 2016 | May 2018 | Abandon | 17 | 2 | 0 | No | No |
| 15309994 | Method of Producing Organic Compounds | November 2016 | March 2019 | Abandon | 28 | 0 | 1 | No | No |
| 15342140 | ENZYME COMPOSITION FOR THERAPEUTIC MANAGEMENT OF MUSCLE SORENESS | November 2016 | August 2020 | Abandon | 45 | 3 | 1 | Yes | No |
| 15307506 | CELLULOSE-BASED BIOMASS JUICING METHOD AND GAS FUEL PREPARATION METHOD | October 2016 | March 2019 | Abandon | 28 | 1 | 0 | No | No |
| 15288870 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGENIC GROWTH | October 2016 | November 2018 | Abandon | 26 | 1 | 0 | No | No |
| 15278126 | CELL CULTURE METHOD AND CELL CULTURE SYSTEM | September 2016 | April 2021 | Abandon | 54 | 3 | 1 | Yes | No |
| 15273126 | ANIMAL CELL REGENERATION SPEED CONTROLLING METHOD AND ANIMAL CELL REGENERATION SPEED CONTROLLER | September 2016 | June 2020 | Abandon | 60 | 2 | 1 | Yes | No |
| 15117742 | BIOMASS TRANSFORMATION | August 2016 | July 2020 | Abandon | 47 | 2 | 1 | No | No |
| 15101991 | A METHOD FOR PREPARING A DAIRY PRODUCT HAVING A STABLE CONTENT OF GALACTO-OLIGOSACCHARIDE(S) | June 2016 | January 2020 | Allow | 43 | 2 | 1 | No | No |
| 15135222 | USE OF ORP FOR CHARACTERIZING STROKE PATIENTS | April 2016 | April 2020 | Abandon | 48 | 2 | 1 | No | Yes |
| 14916255 | CULTURING METHOD FOR BACTERIA BELONGING TO GENUS COLLIMONAS AND STORAGE METHOD | March 2016 | March 2019 | Abandon | 36 | 1 | 1 | No | No |
| 15058443 | MICROORGANISMS THAT EXTRACELLULARLY SECRETE LIPIDS AND METHODS OF PRODUCING LIPID AND LIPID PARTICLES ENCAPSULATING LIPIDS USING SAID MICROORGANISMS | March 2016 | September 2018 | Allow | 30 | 1 | 1 | Yes | No |
| 15013550 | FRACTIONATION AND SEPARATION OF LIGNOCELLULOSIC BIOMASS CARBOHYDRATES BY TWO STAGE STEAM PRETREATMENT | February 2016 | October 2018 | Allow | 32 | 2 | 0 | Yes | No |
| 14847695 | METHODS AND USES OF MEDIASTINAL PLEURA TISSUE FOR VARIOUS STENT AND OTHER MEDICAL APPLICATIONS | September 2015 | February 2023 | Abandon | 60 | 7 | 1 | Yes | No |
| 14397378 | METHODS FOR MODIFICATION OF TISSUES | October 2014 | March 2019 | Abandon | 52 | 2 | 2 | No | No |
| 14325040 | POLYPEPTIDES HAVING ANTIVIRAL ACTIVITY AND METHODS FOR USE THEREOF | July 2014 | June 2015 | Allow | 12 | 0 | 0 | No | No |
| 14300686 | METHOD OF CULTURING CELLS | June 2014 | July 2015 | Abandon | 13 | 1 | 0 | No | No |
| 14270623 | HMGB1 AND ANTI-HMGB1 ANTIBODIES FOR THE PROGNOSTIC OF NEUROLOGICAL DISORDERS | May 2014 | June 2015 | Allow | 14 | 0 | 0 | No | No |
| 14355108 | METHOD FOR ISOLATING CELLS AND BIOPARTICLES | April 2014 | February 2017 | Abandon | 33 | 1 | 0 | No | No |
| 14096916 | REPLICATION DEFICIENT RECOMBINANT VIRUSES EXPRESSING ANTIGENS REGULATED BY TRANSCRIPTIONAL CONTROL ELEMENTS COMPRISING MULTIPLE ELEMENTS | December 2013 | June 2015 | Allow | 18 | 1 | 0 | No | No |
| 14052375 | METHOD OF INHIBITING METHANOGENESIS | November 2013 | February 2017 | Abandon | 40 | 1 | 1 | No | No |
| 14075943 | Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines | November 2013 | June 2015 | Allow | 19 | 0 | 1 | No | No |
| 14073112 | MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE | November 2013 | June 2015 | Allow | 20 | 0 | 1 | No | No |
| 14111790 | COMPOSITIONS FOR DETECTING AN INFECTION BY AN HIV-1 VIRUS | October 2013 | June 2015 | Allow | 20 | 1 | 0 | No | No |
| 14027495 | ORGAN ARREST, PROTECTION, PRESERVATION AND RECOVERY | September 2013 | July 2015 | Abandon | 21 | 2 | 1 | No | No |
| 13900750 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | May 2013 | May 2017 | Abandon | 48 | 4 | 1 | No | No |
| 13866060 | CHROMATOGRAPHY METHOD | April 2013 | June 2015 | Allow | 25 | 1 | 1 | No | No |
| 13856354 | SMALL ENZYME-CONTAINING GRANULES | April 2013 | August 2015 | Abandon | 28 | 2 | 0 | No | No |
| 13688468 | INTRADERMAL INFLUENZA VACCINE | November 2012 | February 2017 | Abandon | 51 | 2 | 0 | No | Yes |
| 13641590 | NANOZYMES, METHODS OF MAKING NANOZYMES, AND METHODS OF USING NANOZYMES | October 2012 | May 2018 | Allow | 60 | 2 | 1 | No | Yes |
| 13549211 | IDENTIFYING AND MEASURING RETICULOCYTES | July 2012 | October 2014 | Allow | 27 | 2 | 1 | Yes | No |
| 13520021 | HIGH THROUGHPUT CELL-BASED HPV IMMUNOASSAYS FOR DIAGNOSIS AND SCREENING OF HPV-ASSOCIATED CANCERS | June 2012 | May 2015 | Allow | 35 | 3 | 1 | Yes | No |
| 13282006 | METHODS FOR REMOVING PLASMA | October 2011 | July 2015 | Abandon | 44 | 0 | 1 | No | No |
| 13269195 | Magnetic Pigment | October 2011 | September 2016 | Abandon | 60 | 2 | 0 | No | Yes |
| 13207905 | Treatment of Diabetes with Pancreatic Endocrine Precursor Cells | August 2011 | May 2017 | Abandon | 60 | 7 | 0 | No | Yes |
| 13185386 | NEUTRALIZING MOLECULES TO VIRAL ANTIGENS | July 2011 | June 2015 | Allow | 47 | 1 | 1 | No | No |
| 13028819 | NUCLEOSIDE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS | February 2011 | January 2017 | Abandon | 60 | 3 | 1 | No | Yes |
| 12792259 | METHOD OF FILTERING PLATELETS TO REMOVE ANTIPLATELET AND ANTICOAGULANT AGENTS | June 2010 | January 2015 | Allow | 55 | 2 | 1 | Yes | No |
| 12226648 | MAGNETIC RESONANCE-DETECTABLE, ULTRASOUND-DETECTABLE AND/OR RADIOPAQUE MICROCAPSULES AND USES THEREOF | July 2009 | August 2015 | Abandon | 60 | 3 | 1 | No | No |
| 12296413 | PROTEASE DETECTION PRODUCT | November 2008 | July 2015 | Abandon | 60 | 3 | 1 | No | No |
| 12230566 | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells | September 2008 | October 2016 | Abandon | 60 | 2 | 0 | Yes | Yes |
| 12140664 | METHOD OF TISSUE VASCULARIZATION | June 2008 | December 2015 | Abandon | 60 | 4 | 1 | No | Yes |
| 11917169 | Method For Cell Culture | December 2007 | May 2016 | Abandon | 60 | 2 | 0 | No | Yes |
| 11920782 | Protein-Immobilized membrane, method for immobilization of protein, enzyme-immobilized electrode, and biosensor | November 2007 | February 2016 | Abandon | 60 | 4 | 1 | No | No |
| 11708175 | ALTERNATE READING FRAME HEPATITIS C VIRUS PEPTIDES AND USES THEREOF | February 2007 | March 2010 | Allow | 37 | 1 | 2 | Yes | No |
| 11640470 | Tissue control rods for sheet-based tissue engineering | December 2006 | July 2015 | Abandon | 60 | 3 | 1 | Yes | No |
| 10577893 | HCV REPLICONS CONTAINING NS5B FROM GENETYPE 2B | May 2006 | September 2012 | Allow | 60 | 0 | 1 | Yes | No |
| 11388135 | CHARGED LIPOPROTEIN COMPLEXES AND THEIR USES | March 2006 | December 2011 | Allow | 60 | 4 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUMPHREY, LOUISE WANG ZHIYING.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUMPHREY, LOUISE WANG ZHIYING works in Art Unit 1657 and has examined 103 patent applications in our dataset. With an allowance rate of 30.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner HUMPHREY, LOUISE WANG ZHIYING's allowance rate of 30.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUMPHREY, LOUISE WANG ZHIYING receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUMPHREY, LOUISE WANG ZHIYING is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by HUMPHREY, LOUISE WANG ZHIYING. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.7% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 41.7% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 70.6% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.7% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.